Skip to content

Text Size: AAA

Leadership and Structure

Amylin is prepared to execute on an extraordinary opportunity in 2012, with a focus on the following value-driving opportunities:

  • Successfully launch BYDUREON™ (exenatide extended-release for injectable suspension) in the United States (U.S.)
  • Secure a partner outside the U.S. for exenatide
  • Maximize the value of BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection
  • Advance the metreleptin and exenatide suspension development programs
  • Continue focused financial discipline